@article{crownshaw_mcentee_nolan_gieger_2020, title={Evaluation of variables associated with outcomes in 41 dogs with incompletely excised high-grade soft tissue sarcomas treated with definitive-intent radiation therapy with or without chemotherapy}, volume={256}, ISSN={["1943-569X"]}, DOI={10.2460/javma.256.7.783}, abstractNote={Abstract}, number={7}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Crownshaw, Abigail H. and McEntee, Margaret C. and Nolan, Michael W. and Gieger, Tracy L.}, year={2020}, month={Apr}, pages={783–791} }
 @article{mcentee_thrall_1995, title={USE OF PORTAL RADIOGRAPHY TO INCREASE ACCURACY OF DOSE DELIVERY IN RADIATION-THERAPY}, volume={36}, ISSN={["1058-8183"]}, DOI={10.1111/j.1740-8261.1995.tb00215.x}, abstractNote={Port films were acquired for all radiation therapy patients (n = 132) treated over a thirteen month period to 1] assist in initial treatment field set‐up on Day 1, 2] for quality assurance with a second port film taken on Day 7 of radiation therapy, and 3] as a means to document the radiation treatment field as a part of the patients permanent medical record. Port films were used for both patients treated with a definitive course of radiation (n = 97 patients), and those treated palliatively (n = 35 patients). The portal radiographs were valuable in terms of the initial set‐up, and to correct for any positioning or other errors at the time of the one week recheck. Changes were made, based on the initial port film on Day 1, in 53% and 57% of treatment fields for palliative and definitive radiation patients, respectively. The changes made in both definitively and palliatively irradiated patients were usually in field position, an increase in field size to include all of the tumor, or a decrease in field size to spare normal tissue. Fewer changes were necessary based on the Day 7 recheck port films, but these day‐7 rechecks are recommended for quality control. Based on the high frequency of changes introduced because of the initial port film findings, it is recommended that port films be incorporated on a routine basis in veterinary radiation therapy.}, number={1}, journal={VETERINARY RADIOLOGY & ULTRASOUND}, author={MCENTEE, MC and THRALL, DE}, year={1995}, pages={69–77} }
 @article{page_mcentee_williams_george_price_novotney_hauck_riviere_dewhirst_thrall_1994, title={EFFECT OF WHOLE-BODY HYPERTHERMIA ON CARBOPLATIN DISPOSITION AND TOXICITY IN DOGS}, volume={10}, ISSN={["0265-6736"]}, DOI={10.3109/02656739409012373}, abstractNote={Fifty dogs with refractory or disseminated spontaneous tumours were evaluated in two independent phase I studies using either carboplatin (CBDCA) alone or CBDCA plus whole body hyperthermia (WBH). CBDCA was administered as a 30 min infusion at the onset of the plateau phase of WBH in dogs receiving combined treatment. Serum samples were collected and drug disposition was determined in both treatment groups. The dose-effect relationship was mathematically described with a logistic regression model developed from categorical toxicity data accumulated throughout the first two treatment courses in all dogs. The maximum tolerated dose (MTD) was defined as that dose which resulted in a 50% probability of achieving moderate or severe toxicity. The only toxicities observed were neutropenia and thrombocytopenia, which were dose-dependent. The nadir occurred between 7 and 14 days following treatment. A significant decrease in the area under the serum CBDCA versus time curve for dogs undergoing WBH was consistent with increased tissue binding of the drug as well as increased urinary eliminations. Serum AUC values determined following the first course of treatment were predictive of subsequent toxicity in both treatment groups. The MTD (95%CI) for CBDCA and CBDCA/WBH were estimated to be 318(44) and 239(51) mg/M2 respectively (p = 0.08). A randomized phase II evaluation should be initiated to determine if a therapeutic gain can be achieved using combined CBDCA and WBH. Further refinement of the CBDCA dose in such a trial should be based on both pharmacokinetic parameters and normal tissue response.}, number={6}, journal={INTERNATIONAL JOURNAL OF HYPERTHERMIA}, author={PAGE, RL and MCENTEE, MC and WILLIAMS, PL and GEORGE, SL and PRICE, GS and NOVOTNEY, CA and HAUCK, ML and RIVIERE, JE and DEWHIRST, MW and THRALL, DE}, year={1994}, pages={807–816} }
 @article{mcentee_page_novotney_thrall_1993, title={PALLIATIVE RADIOTHERAPY FOR CANINE APPENDICULAR OSTEOSARCOMA}, volume={34}, ISSN={["1058-8183"]}, DOI={10.1111/j.1740-8261.1993.tb02022.x}, abstractNote={Fifteen dogs with appendicular osteosarcoma (presumptive diagnosis, n = 6 dogs; biopsy confirmed, n = 9 dogs) were treated with palliative radiotherapy. Treatment entailed a total of three 10 Gy fractions of60Co radiation delivered over a three week period on days 0, 7 and 21, for a total dose of 30 Gy. Twelve dogs experienced improvement in limb function 7–22 days after the start of treatment. Long term followup was available for nine of the twelve responders. The duration of response was 17–288 days (n = 9 dogs; median = 130 days; mean = 116 days). Response duration did not appear to be related to initial tumor size. Palliative radiotherapy can result in improved limb function in dogs with appendicular osteosarcoma.}, number={5}, journal={VETERINARY RADIOLOGY & ULTRASOUND}, author={MCENTEE, MC and PAGE, RL and NOVOTNEY, CA and THRALL, DE}, year={1993}, pages={367–370} }
 @article{page_thrall_george_price_heidner_mcentee_novotney_hauck_dewhirst_1992, title={QUANTITATIVE ESTIMATION OF THE THERMAL DOSE-MODIFYING FACTOR FOR CIS-DIAMMINEDICHLOROPLATINUM (CDDP) IN TUMOR-BEARING DOGS}, volume={8}, ISSN={["0265-6736"]}, DOI={10.3109/02656739209005024}, abstractNote={A statistical method for estimating clinical toxicity was used to determine a theoretical isoeffect dose-modifying factor for dogs with disseminated or refractory neoplasia treated with cis-diammine dichloroplatinum (II) plus whole-body hyperthermia or CDDP alone. CDDP was administered every 3 weeks with vigorous saline hydration to 54 dogs (CDDP alone n = 21, CDDP/WBH n = 33) that were eligible for entry into this non-randomized study. CDDP was administered during the plateau phase of WBH in dogs receiving combined therapy. Acute toxicity included myelosuppression (CDDP n = 7; CDDP/WBH n = 5), nephrotoxicity (CDDP n = 1, CDDP/WBH n = 1) and respiratory distress (CDDP/WBH n = 2). Eight dogs experienced chronic renal dysfunction as a result of CDDP (n = 2) or CDDP/WBH (n = 6). A theoretical thermal dose-modifying factor was determined for both acute and cumulative toxicity by comparing the maximum tolerated dose of each treatment group. The maximum tolerated dose (MTD) of CDDP +/- WBH was defined as that dose producing a 50% incidence of moderate acute toxicity or acute plus mild chronic toxicity as estimated from logistic regression analysis of the toxicity data. The MTD (+/- .standard error) of CDDP/WBH for acute toxicity only was 54.6 (4.3) mg/M2 and for CDDP alone the MTD was 73.6 (40) mg/M2. Thus, the isoeffect dose-modifying factor for acute toxicity was 1.35 (0.12). The MTD (SE) of CDDP/WBH for cumulative toxicity (acute plus chronic toxicity) was 46.4 (2.7) mg/M2 and for CDDP alone waas 70.0 (2.9) mg/M2. The isoeffect dose-modifying factor for total cumulative toxicity was 1.5 (0.1).(ABSTRACT TRUNCATED AT 250 WORDS)}, number={6}, journal={INTERNATIONAL JOURNAL OF HYPERTHERMIA}, author={PAGE, RL and THRALL, DE and GEORGE, SL and PRICE, GS and HEIDNER, GL and MCENTEE, MC and NOVOTNEY, CA and HAUCK, ML and DEWHIRST, MW}, year={1992}, pages={761–769} }
 @article{mcentee_page_cline_thrall_1992, title={RADIATION PNEUMONITIS IN 3 DOGS}, volume={33}, ISSN={["1058-8183"]}, DOI={10.1111/j.1740-8261.1992.tb00132.x}, abstractNote={Radiation pneumonitis developed within the radiation treatment field in three dogs with soft tissue sarcomas located on or adjacent to the thoracic wall. Radiographic signs compatible with a diagnosis of radiation pneumonitis developed from one (n = 2 dogs) to two (n = 1 dog) months after completion of therapy. The initial radiographic sign was an alveolar infiltrate in all three dogs. At subsequent examinations at variable time periods after treatment, radiographic findings included: bronchiectasis (n = 3 dogs), alveolar infiltrate (n = 2 dogs), decreased lung volume (n = 2 dogs), and unstructured interstitial opacification (n = 1 dog). Necropsy examination of one dog at fourteen months after the completion of radiotherapy showed evidence of pulmonary fibrosis within the irradiated lung. Necropsy examination of the second dog did not show any evidence of radiation induced changes. It is possible that histopathologic examination did not include irradiated lung. No clinical signs that could be attributed to the radiation pneumonitis were observed in any dog. It appears that approximately 25% of the lung can be safely irradiated to high doses, if indicated, in order to deliver an adequate dose of radiation to a primary tumor site.}, number={4}, journal={VETERINARY RADIOLOGY & ULTRASOUND}, author={MCENTEE, MC and PAGE, RL and CLINE, JM and THRALL, DE}, year={1992}, pages={190–197} }
 @article{mcentee_page_heidner_cline_thrall_1991, title={A RETROSPECTIVE STUDY OF 27 DOGS WITH INTRANASAL NEOPLASMS TREATED WITH COBALT RADIATION}, volume={32}, ISSN={["0196-3627"]}, DOI={10.1111/j.1740-8261.1991.tb00096.x}, abstractNote={Twenty‐seven dogs with sinonasal neoplasms were treated with cobalt radiation. Cytoreductive surgery was performed in six of the patients prior to initiation of irradiation. Dogs received from 4,180 to 5,400 cGy on a Monday/Wednesday/Friday schedule given in 10 to 12 fractions over a four week period. All dogs had a computed tomography (CT) based, computer generated radiation treatment plan. Survival time ranged from 2.5 to 46.0 months with a mean and median of 20.7 ± 3.3 and 12.8 months, respectively. The one‐ and two‐year survival rates were 59% and 22%. Survival time compares favorably to those reported previously for dogs treated with cytoreductive surgery and orthovoltage x‐rays. Survival time is longer than that reported previously using megavoltage radiation alone or in conjunction with surgery. It is likely that the improved survival reported herein is, at least in part, related to the use of computed tomography for tumor localization and computer generation of the treatment plan. No prognostic variables were identified in the present study. Survival time was not significantly different between dogs with carcinoma versus sarcoma. There was no significant difference between patients that had undergone cytoreductive surgery prior to radiotherapy, and those patients treated with radiotherapy alone.}, number={3}, journal={VETERINARY RADIOLOGY}, author={MCENTEE, MC and PAGE, RL and HEIDNER, GL and CLINE, JM and THRALL, DE}, year={1991}, pages={135–139} }
 @inproceedings{page_riviere_heidner_mcentee_thrall_1989, title={Effect of temperature on cisplatin (CDDP) and carboplatin (CBDCA) pharmacokinetic disposition in dogs}, volume={2}, booktitle={Conference Proceedings}, author={Page, R. L. and Riviere, J. E. and Heidner, G. L. and McEntee, M. C. and Thrall, D. E.}, year={1989}, pages={499–501} }